We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Corcept Therapeutics and Xceleron Sign Agreement for Microdosing Study Using Accelerator Mass Spectrometry
News

Corcept Therapeutics and Xceleron Sign Agreement for Microdosing Study Using Accelerator Mass Spectrometry

Corcept Therapeutics and Xceleron Sign Agreement for Microdosing Study Using Accelerator Mass Spectrometry
News

Corcept Therapeutics and Xceleron Sign Agreement for Microdosing Study Using Accelerator Mass Spectrometry

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Corcept Therapeutics and Xceleron Sign Agreement for Microdosing Study Using Accelerator Mass Spectrometry"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Corcept Therapeutics and Xceleron have announced an agreement for a human microdosing study of one of Corcept’s new chemical entities, a selective GR-II antagonist, utilizing Xceleron’s Accelerator Mass Spectrometry (AMS) technology.

In early 2003, Corcept initiated a discovery research program to identify and patent selective GR-II antagonists to develop a pipeline of products for proprietary use. Three distinct series of GR-II antagonists were identified. These compounds appear to be as potent as Corcept’s lead product CORLUX® in blocking cortisol but, unlike CORLUX, they do not block the progesterone or other steroid receptors.

Corcept will evaluate one of the compounds, one which develops particularly high plasma and brain concentrations in an animal model, in a human microdosing study using Xceleron’s AMS technology.

Joseph K. Belanoff, M.D., Chief Executive Officer of Corcept said “We look forward to testing the bioavailability of our proprietary specific cortisol receptor antagonists in man. There are many potential clinical uses for cortisol blocking agents, particularly those that do not block the activity of other hormones. Our collaboration with Xceleron, and the use of their highly innovative approach, will save Corcept significant time and cost.”

Xceleron will carry out the work using ultra-sensitive AMS. This sensitive measuring device can enable human drug-metabolite profiling to be performed in the early stages of clinical development. This type of analysis allows drug developers to detect and measure ultra-low levels of both known and previously unknown metabolites producing data that isn’t available using other analytical techniques.

Early human profiling also helps identify the most suitable species for use in long term toxicology and pharmacology studies.

Advertisement